Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | CTSB | P07858 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | CTH | P32929 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23698778 | 0.94 | MAPT (0.53) | MAPTALDH1A1CTSBLMNASMN1; SMN2 | |
| SCHEMBL23698745 | 0.91 | CTSB (0.48) | MAPTALDH1A1CTSBLMNASMN1; SMN2 | |
| SCHEMBL23698711 | 0.91 | CTSB (0.48) | MAPTALDH1A1CTSBLMNASMN1; SMN2 | |
| SCHEMBL23698653 | 0.91 | CTSB (0.48) | MAPTALDH1A1CTSBLMNASMN1; SMN2 | |
| SCHEMBL23698779 | 0.90 | MAPT (0.49) | MAPTALDH1A1CTSBLMNASMN1; SMN2 | |
| SCHEMBL21816898 | 0.90 | MAPT (0.56) | MAPTALDH1A1CTSBLMNASMN1; SMN2 | |
| SCHEMBL23715371 | 0.89 | LMNA (0.53) | MAPTALDH1A1CTSBLMNASMN1; SMN2 | |
| SCHEMBL23698719 | 0.89 | CTSB (0.48) | MAPTALDH1A1CTSBLMNASMN1; SMN2 | |
| SCHEMBL31229275 | 0.89 | LMNA (0.53) | MAPTALDH1A1CTSBLMNASMN1; SMN2 | |
| SCHEMBL23698666 | 0.87 | MAPT (0.52) | MAPTALDH1A1CTSBLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12152048-B2 | Nitroxoline prodrug and use thereof | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2024-11-26 | — | — | US | disclosed |
| US-20210363165-A1 | NITROXOLINE PRODRUG AND USE THEREOF | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2021-11-25 | — | — | US | disclosed |
| US-20210363165-A1 | NITROXOLINE PRODRUG AND USE THEREOF | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2021-11-25 | — | — | US | disclosed |
| EP-3858814-A1 | NITROXOLINE PRODRUG AND USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858814-A1 | NITROXOLINE PRODRUG AND USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12152048-B2 | Nitroxoline prodrug and use thereof | NOS1, NOS2, NNT | MAPT 2243/4885ALDH1A1 706/4885CTSB 2242/4885 |
| US-20210363165-A1 | NITROXOLINE PRODRUG AND USE THEREOF | NOS1, NOS2, NNT | MAPT 2243/4885ALDH1A1 706/4885CTSB 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.